Every 8-K that Humacyte, Inc. Warrant (HUMAW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HUMAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HUMAW filings page.
Humacyte, Inc. reported second quarter 2026 results, highlighting clinical and commercial progress alongside continued losses. For the quarter ended June 30, 2026, total revenue was $406,000, up from $301,000 a year earlier, driven by Symvess product revenue of $0.4 million versus $0.1 million in 2025.
Loss from operations was $27.0 million, with a net loss of $36.8 million compared with a net loss of $37.7 million in the prior-year quarter. For the first six months of 2026, the company recorded a net loss of $54.4 million versus net income of $1.5 million in the first half of 2025.
Humacyte ended June 30, 2026 with $79.9 million in cash and cash equivalents, up from $50.5 million at December 31, 2025, and stockholders’ equity of $31.3 million, up from $3.1 million. The company reported breakthrough Phase 3 results for its acellular tissue engineered vessel in dialysis access, plans a supplemental BLA filing in the second half of 2026, and is preparing a Phase 2a CABG study under an accepted IND.
Humacyte, Inc. received a Nasdaq notice that its common stock bid price closed below the $1.00 per share minimum for 30 consecutive business days ended July 30, 2026, violating Nasdaq Listing Rule 5450(a)(1).
Under Nasdaq Listing Rule 5810(c)(3)(A), Humacyte has 180 calendar days, until January 27, 2027, to regain compliance by achieving a closing bid of at least $1.00 per share for a minimum of 10 consecutive business days. The notice has no immediate effect on the Nasdaq Global Select Market listing, trading symbol HUMA, or on business operations, while the company monitors its stock price and evaluates options.
Humacyte, Inc. entered into an underwriting agreement for a public offering of its common stock. The company is issuing 47,619,048 shares at a public offering price of $1.05 per share, with underwriters holding a 30‑day option to buy up to 7,142,857 additional shares.
Gross proceeds are expected to be $50 million, with net proceeds of about $46.80 million, or $53.85 million if the option is fully exercised. Humacyte plans to use the cash to commercialize its Symvess product, support a planned Biologics License Application supplement in a hemodialysis indication, advance its pipeline, and for working capital and general corporate purposes.
Humacyte, Inc. reported positive interim Phase 3 results for its acellular tissue engineered vessel (ATEV) in female dialysis patients. In the V012 study’s prespecified analysis of the first 80 patients, ATEV met the primary endpoint, delivering an average of 91 more catheter-free days than autologous arteriovenous fistula, the current standard of care.
ATEV patients achieved 220 catheter-free days versus 129 with fistula (p=0.00070) and showed substantially lower infection rates. Based on these results, enrollment will stop and follow-up will continue, and Humacyte plans to file a supplemental Biologic License Application with the FDA in the second half of 2026 for high-risk end-stage kidney disease patients.
Humacyte, Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders approved an amendment to the Certificate of Incorporation increasing authorized common shares from 350,000,000 to 550,000,000, which became effective upon filing in Delaware on June 9, 2026.
As of the April 23, 2026 record date, 222,019,108 common shares were outstanding, and 127,474,086 shares, or about 57.41%, were represented to form a quorum. Stockholders elected three Class II directors, approved on an advisory basis the compensation of named executive officers and chose to hold future say-on-pay votes annually.
They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 and formally approved the increase in authorized common stock. No broker non-votes were recorded on the auditor ratification or share authorization proposals.
Humacyte, Inc. has regained compliance with Nasdaq’s minimum bid price rule. The company had previously been notified that its common stock traded below the required $1.00 per share bid price for 30 consecutive business days ended May 1, 2026.
To cure the issue, Humacyte’s stock needed to close at or above $1.00 for at least 10 consecutive business days before November 2, 2026. On June 5, 2026, Nasdaq informed the company that this condition was met and that its listing on The Nasdaq Global Select Market is now in good standing, with the matter considered closed.
Humacyte, Inc. received a Nasdaq notice that its common stock bid price was below the required $1.00 per share for 30 consecutive business days ended May 1, 2026, putting it out of compliance with Nasdaq Listing Rule 5450(a)(1).
The company has 180 calendar days, until November 2, 2026, for its closing bid price to be at least $1.00 per share for a minimum of 10 consecutive business days to regain compliance. Trading of the stock and the company’s operations and SEC reporting continue unchanged for now, but there is explicit delisting risk if compliance is not restored.
Humacyte, Inc. entered a Third Amendment to its distribution agreement with Fresenius Medical Care, giving Humacyte the sole right to develop, manage regulatory matters for, and commercialize its 6 millimeter acellular tissue engineered vessel, branded Symvess, on a worldwide basis.
In return, Humacyte will pay Fresenius low-single-digit royalties on net sales of Symvess outside the U.S., after a two-year royalty-free period following launch in each country, while existing U.S. royalty rates from mid-single digits to low double digits remain in place and Fresenius stays obligated to adopt Symvess as a standard of care where supported. Humacyte highlights that this realignment supports its planned international expansion and potential indication-specific partnerships, while Symvess currently holds FDA approval only for extremity vascular trauma and remains investigational for other uses.
Humacyte, Inc. is raising $20 million through a registered direct offering of 25,000,000 shares of common stock at $0.80 per share. After placement fees and expenses, net proceeds are expected to be about $18.4 million.
The cash will support commercialization of Symvess in the vascular trauma indication, a planned Biologics License Application supplement for a hemodialysis use, related Phase 3 activities, broader pipeline development, and general corporate purposes. The offering, led by institutional investors, is expected to close on or about March 20, 2026, subject to customary conditions.
Humacyte, Inc. reported a material event on an Form 8-K documenting Amendment No. 2 to a Revenue Interest Purchase Agreement executed on September 17, 2025. The amendment names the parties as Humacyte Global, Inc., Humacyte, Inc. and the purchasers TPC Investments III LP, TPC Investment Solutions LP and Hook SA LLC.
The filing indicates the inclusion of the amendment as an exhibit and an Inline XBRL cover page file. No financial terms, changes to covenants, or quantitative impacts were disclosed in the provided text, so the filing primarily records the contractual amendment rather than operational results.